explore -WSS

explore

author：leisure time 2025-10-02 22:24:45 - browse：131

Kevin Sayer, CEO of Dexcom Dexcom

For years, diabetes tech company Dexcom has been striving to get its continuous glucose monitors into the hands of type 2 diabetes patients. Last week at the American Diabetes Association’s conference, the company unveiled plans for software built entirely for these patients, including ones who don’t take insulin.

“We’ve been so focused on things that match the needs of somebody who manages diabetes every minute of every day, and insulin delivery,” Kevin Sayer, CEO of Dexcom, told STAT. “This new product is going to be designed to address the needs of somebody with diabetes who’s not doing that, who has type 2 diabetes and is on other drugs.”

Continuous glucose monitoring is already well-established among people with type 1 diabetes, who rely on constant insulin therapy. The technology, which helps patients noninvasively monitor their blood sugar levels and control their insulin pump in real time, has grown rapidly in use over the years, culminating in a $5 billion market.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： The SUPPORT Act is critical to fighting the opioid crisis

Wikipedia

WSS

Republicans love RFK Jr. What's that tell us about health in 2024?

HHS names first

As obesity drug market grows, telehealth companies court payers

How I ended up pumping milk in a bathroom stall at JPM 2024

GSK to buy asthma

The SUPPORT Act is critical to fighting the opioid crisis

hotspot

explore

hotspot

Hepatitis C has a cure — but many Americans still lack access to it

How to make over

In Memoriam: Notable people who died in 2023

Republicans love RFK Jr. What's that tell us about health in 2024?

How to save PrEP access — and even expand it

FDA advisory panel to debate high blood pressure devices

New air purifier tech could be key to improving indoor air quality

Designating disabled people as health disparity population is crucial

ChatGPT in medicine: STAT answers readers' burning questions

Doulas covered by Medicaid under New York's new plan

hotspot

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

Why liver experts renamed NASH to MASH, and NAFLD to MASLD

Trans patients at the end of life deserve respect and dignity

PBMs are inflating the cost of generic drugs. They must be reined in

Roche's accidental data boosts hopes for anti

Meadows told special counsel he could not recall Trump ever declassifying Mar

hotspot

explore

Wikipedia

Wikipedia